Economic Impact on Kidney Disease Progression and Outcomes

By Staff Writer

March 14, 2024

Introduction:

Chronic Kidney Disease (CKD) remains a significant public health concern, affecting an estimated 850 million people globally. With the rapid rise in CKD prevalence and complications, it is projected to become the fifth most common cause of years of life lost by 2040. On world kidney day we look at the socioeconomic factors influencing CKD progression and the potential of AI in predicting acute kidney disease outcomes.

The Socioeconomic Impact on CKD Progression:

Despite the attention given to socioeconomic status in relation to CKD development and progression, health disparities associated with socioeconomic factors have not reduced worldwide. Even in countries with universal health coverage, income-related disparities associated with CKD are prevalent. Lower income levels are associated with faster CKD progression and a higher risk of initiation of Kidney Replacement Therapies (KRTs). This finding provides crucial information for future health care policies, highlighting the need for more active support beyond financial assistance.

Factors and CKD in Japan:

A recent study in Japan, a country with universal health coverage, found a strong association between lower income levels and faster progression of CKD. These lower income individuals also had a higher risk of starting KRT. The disparities in rapid CKD progression and initiation of KRT across income levels were significant. This occurred despite the country’s comprehensive healthcare coverage and minimal financial obstacles to medical services. These findings suggest that income disparity relates not only to financial barriers to medical care, but also to factors such as health literacy, psychosocial stress, and stress-related behavioural risks.

Key Findings from the Japanese Study:

The study revealed that the risk for the lower income group was over 60% higher than that of the highest income group. This was the case even in a country with almost universal health coverage. They observed this negative monotonic association more prominently among males and those without diabetes. These findings indicate a need to target socioeconomically disadvantaged populations. They underscore the importance of interventions across society to minimise social and behavioural risks for low-income individuals.

The Role of AI in Predicting AKI Outcomes:

Acute Kidney Injury (AKI) complicates 13–18% of hospital admissions in the UK. Predicting which inpatient cases progress to require Renal Replacement Therapy (RRT) remains an unaddressed challenge. Recent research has shown the potential of a Recurrent Neural Network (RNN) in predicting AKI. This AI tool could predict AKI up to 48 hours in advance, the risk of an inpatient with AKI requiring RRT therefore being admitted to a hospital or dying.

Conclusion:

In conclusion, there is a substantial association between low-income levels and the development of impaired kidney function. Moreover, this is seen with rapid CKD progression and initiation of KRT. The findings highlight the importance of society-wide interventions aimed at reducing the social and behavioural risks to individuals in the low-income group. Furthermore, AI has shown promise in predicting AKI progression. If this becomes validated, it could improve patient care while streamlining healthcare resource allocation.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.